Evommune (EVMN) Accumulated Expenses (2024 - 2026)

Evommune (EVMN) has reported Accumulated Expenses for 3 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses changed N/A year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (changed N/A YoY), while the FY2025 annual figure was $4.9 million, up 35.77% from the prior year.
• Accumulated Expenses fell to $4.7 million in Q1 2026 per EVMN's latest filing, from $4.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.9 million in Q4 2025 and bottomed at $2.9 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $4.0 million across 3 years, with a median of $4.2 million in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 35.77% in 2025 and fell as far as 35.77% in 2025.
• Evommune's Accumulated Expenses stood at $3.6 million in 2024, then surged by 35.77% to $4.9 million in 2025, then dropped by 4.05% to $4.7 million in 2026.
• Business Quant data shows EVMN's Accumulated Expenses at $4.7 million in Q1 2026, $4.9 million in Q4 2025, and $2.9 million in Q3 2025.